Investigation of the Clinical Performance of Biatain Fiber Ag on Venous Leg Ulcers

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

50 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-07-31

Study Completion Date

2024-05-17

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The goal of this study is to test a new gelling fiber wound dressing with silver on patients with a venous leg ulcer

Participants will be asked to wear the test dressing in a four weeks period (+/- 2 days) consisting of 6 study visits, and will have the dressing changed once pr. week at the research facility. The wound will be cleaned, assessed and photos will be uploaded to a digital software system.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A RCT Evaluating the Clinical Benefit of a Silver Dressing in the Treatment of Venous Leg Ulcers

NCT05923749

Wound Heal

COMPLETED NA

Biatain Ag vs Biatain in the Treament of Leg Ulcers

NCT00807664

Leg Ulcers

COMPLETED NA

DermaRep™ Device in the Treatment of Venous Leg Ulcers

NCT03699072

Venous Leg Ulcer

COMPLETED NA

An Evaluation of a Fibrillar Collagen Dressing to Treat Chronic, Stalled Lower-extremity Wounds

NCT03723577

Wound

WITHDRAWN NA

An Open, Non-comparative, Multicenter Investigation to Evaluate the Safety and Performance of Exufiber Ag+, a Gelling Fiber Silver Dressing, When Used in Medium to High Exuding Chronic Wounds

NCT05494450

Pressure Ulcer Diabetic Foot Ulcer Venous Leg Ulcer

TERMINATED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

: The clinical investigation is a non-comparative, one-armed, open-labelled, multi-centre study

The test product, Biatain Fiber Ag is a non-CE-marked gelling fiber wound dressing, containing silver. The product is intended for moist wound healing and exudate management of moderate to high exuding wounds.

The overall purpose of this investigation is to obtain clinical data supporting effectiveness of Biatain Fiber Ag to obtain the CE-mark in EU.

The total study duration for the subject will be approximately four weeks, consisting of a four-week test period and 6 study visits (V0/V1, V2, V3, V4 and V5). V5 will also terminate the 4-week study period.

The primary endpoint is Mean area wound reduction. The endpoint is used to evaluate clinical performance in terms of relative wound area reduction as an indication of total wound healing.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Venous Leg Ulcer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

non-comparative, one-armed, open-labelled, multi-centre study

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

main arm

Non comparative - One armed - open labelled Intervention - subjects will wear the test dressing in a four weeks period with planned dressing changes once pr. week.

Group Type OTHER

Biatain Fiber Ag applied to participants

Intervention Type DEVICE

Intervention involving a wound gelling fiber dressing with silver

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Biatain Fiber Ag applied to participants

Intervention involving a wound gelling fiber dressing with silver

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Has signed informed consent
2. Is 18 years or above
3. Is capable of following study procedure (assessed by the investigator).
4. Has a venous leg ulcer that has failed to progress along the expected wound healing trajectory within 4 weeks
5. The shape of the wound should be possible to fit under a 10x10 cm dressing
6. The shape and location of the wound should be suitable for photo capture (assessed by the investigator).
7. Has at least three of five pre-defined clinical signs of infection; pain between two dressing changes, peri-ulcer skin erythema/inflammation, oedema, malodour, or heavy exudate (assessed by the investigator).
8. Has a wound that has medium to high level of exudate (assessed by the investigator).
9. Has an ankle to brachial pressure index (ABPI) of 0.8 -1.3
10. Agrees to wear compression therapy daily in combination with the test dressing
11. Is suitable to use the test product for wound treatment (assessed by the investigator).

Exclusion Criteria

1. Is pregnant/breastfeeding
2. Wound is older than 12 months
3. Wound with exposed tendons or bones or has fistulas
4. Wound which is undermined or tunneling
5. Is currently receiving or has within the past 60 days received radio- and/or chemotherapy (low doses radio- and/or chemotherapy is allowed for other indications than cancer if assessed by investigator not to influence study wound area)
6. Known history of skin sensitivity to any components of the treatment dressings
7. Intake of antibiotics within one week before the start of the enrolment
8. Participation in any other clinical studies that can compromise this study treatment (assessed by the investigator).

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No